Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for ...

The European Union's drugs regulator on Thursday recommended approval for Eisai and Biogen's Leqembi in some patients with ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

Diagnosing Alzheimer's years before you have symptoms. That's where research takes us. New, effective treatments are making a ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

An 80-something patient came in for an annual visit recently and was worried that recent memory lapses might be symptoms of ...

Researchers map the unique genetic regulation of proteins in human cerebrospinal fluid, identifying potential targets for ...

Cannabis is emerging as a tool in dementia care, offering relief from anxiety and agitation when traditional medications fall ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Ann Lange was diagnosed with Alzheimer's in 2015, but with the help of clinical trials her disease has not progressed past ...